Patents by Inventor Yulia Rozen

Yulia Rozen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy
    Patent number: 7172749
    Abstract: Radiolabeled epidermal growth factor receptor tyrosine kinase (EGFR-TK) irreversible inhibitors and their use as biomarkers for medicinal radioimaging such as Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) and as radiopharmaceuticals for radiotherapy are disclosed.
    Type: Grant
    Filed: September 11, 2003
    Date of Patent: February 6, 2007
    Assignees: Yissum Research Development Company of the Hebrew University of Jerusalem, Hadasit Medical Research Services and Development Ltd.
    Inventors: Alexander Levitzki, Eyal Mishani, Giuseppina Ortu, Iris Ben-David, Yulia Rozen
  • Novel irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and uses thereof for therapy and diagnosis
    Publication number: 20060025430
    Abstract: Novel epidermal growth factor receptor tyrosine kinase (EGFR-TK) irreversible inhibitors, pharmaceutical compositions including same and their use in the treatment of EGFR-TK related diseases or disorders are disclosed. Novel radiolabeled EGFR-TK irreversible inhibitors as their use as biomarkers for medicinal radioimaging such as Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) and as radiopharmaceuticals for radiotherapy are further disclosed.
    Type: Application
    Filed: July 21, 2005
    Publication date: February 2, 2006
    Inventors: Eyal Mishani, Yulia Rozen, Galith Abourbeh, Alexander Levitzki
  • Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy
    Publication number: 20040265228
    Abstract: Radiolabeled epidermal growth factor receptor tyrosine kinase (EGFR-TK) irreversible inhibitors and their use as biomarkers for medicinal radioimaging such as Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) and as radiopharmaceuticals for radiotherapy are disclosed.
    Type: Application
    Filed: September 11, 2003
    Publication date: December 30, 2004
    Inventors: Alexander Levitzki, Eyal Mishani, Giuseppina Ortu, Iris Ben-David, Yulia Rozen
  • Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy
    Patent number: 6562319
    Abstract: Radiolabeled epidermal growth factor receptor tyrosine kinase (EGFR-TK) irreversible inhibitors and their use as biomarkers for medicinal radioimaging such as Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) and as radiopharmaceuticals for radiotherapy are disclosed.
    Type: Grant
    Filed: March 12, 2001
    Date of Patent: May 13, 2003
    Assignees: Yissum Research Development Company of the Hebrew University of Jerusalem, Hadasit Medical Research Services and Development Ltd.
    Inventors: Eyal Mishani, Iris Ben-David, Yulia Rozen, Gluseppina Ortu, Alexander Levitzki
  • Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy
    Publication number: 20020128553
    Abstract: Radiolabeled epidermal growth factor receptor tyrosine kinase (EGFR-TK) irreversible inhibitors and their use as biomarkers for medicinal radioimaging such as Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) and as radiopharmaceuticals for radiotherapy are disclosed.
    Type: Application
    Filed: March 12, 2001
    Publication date: September 12, 2002
    Applicant: Hadasit Medical Research Services and Development Ltd.
    Inventors: Eyal Mishani, Iris Ben-David, Yulia Rozen, Gluseppina Ortu, Alexander Levitzki
  • Epidermal growth factor receptor binding compounds for positron emission tomography
    Patent number: 6126917
    Abstract: A radiolabeled compound of a formula: ##STR1## is described. R1 and R2 are each independently selected from the group consisting of hydrogen, alkyl, hydroxy, alkoxy, halo, haloalkyl, carboxy, carbalkoxy and salts thereof; and A, B, C and D are each independently selected from the group consisting of a hydrogen and an electron withdrawing group, provided that at least one of A, B, C and D is [18]fluorine.
    Type: Grant
    Filed: June 1, 1999
    Date of Patent: October 3, 2000
    Assignee: Hadasit Medical Research Services and Development Ltd.
    Inventors: Eyal Mishani, Thomas Bonasera, Giuseppina Ortu, Yulia Rozen, Aviv Gazit, Alexander Levitzki